Bradykinin is a 9-amino-acid vasoactive peptide generated from high-molecular-weight kininogen (HMWK) by kallikrein enzymes during tissue injury, inflammation, and allergic responses. It is one of the most potent endogenous mediators of vascular permeability, nociceptive sensitization, and smooth muscle contraction, acting primarily through B2 (constitutive) and B1 (inflammation-inducible) G-protein-coupled receptors. Bradykinin has a short half-life (seconds to minutes) due to rapid enzymatic degradation by ACE (angiotensin-converting enzyme) and other peptidases.
Imagine bradykinin as an emergency alarm pulled during a building fire. The moment tissue is damaged—whether by infection, trauma, or allergic insult—the alarm (kallikrein) clips a security tag off a coiled cable (kininogen), releasing the active alarm signal (bradykinin). This alarm has three immediate effects: (1) it blasts open the fire exits (vasodilation), (2) it unlocks all the side doors so firefighters can flood in (increased vascular permeability → edema), and (3) it activates a piercing siren that makes everyone acutely aware of danger (pain sensitization via nociceptor activation). The building's sprinkler system (ACE enzyme) is designed to shut off this alarm within seconds to prevent chaos—but if you disable the sprinkler (ACE inhibitor drugs), the alarm keeps ringing, causing persistent cough from airway irritation or swelling in unexpected places (angioedema). Bradykinin doesn't just announce damage; it actively reshapes the inflammatory landscape to prioritize immediate response.
Kininogen cleavage:
- High-molecular-weight kininogen (HMWK) circulates in plasma bound to prekallikrein
- Tissue injury or contact activation (Factor XIIa in coagulation cascade) activates kallikrein
- Plasma kallikrein or tissue kallikreins (serine proteases) cleave HMWK → release bradykinin (9 amino acids: Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg)
Receptor activation:
- B2 receptor (constitutive, GPCR): present on endothelial cells, smooth muscle, neurons
- Bradykinin binds → Gq protein activation → phospholipase C (PLC) → IP3 + DAG
- IP3 → Ca²⁺ release from intracellular stores
- DAG → protein kinase C (PKC) activation
- Ca²⁺ influx → endothelial Nitric Oxide synthase (eNOS) activation → NO production → vasodilation
- Ca²⁺ → phospholipase A2 (PLA2) → arachidonic acid release → COX-2 → PGE2, prostacyclin (PGI2) → further vasodilation and pain sensitization
- B1 receptor (inducible, GPCR): upregulated during inflammation by IL-1β, TNF-α
- Similar Gq signaling cascade
- Preferentially binds des-Arg9-bradykinin (bradykinin metabolite)
- Contributes to chronic inflammatory pain and hyperalgesia
Downstream effects:
- Vasodilation: NO + PGI2 → vascular smooth muscle relaxation
- Vascular permeability: Endothelial cell contraction via myosin light chain kinase → intercellular gaps → plasma extravasation → edema
- Pain sensitization: Direct activation of nociceptive terminals (A-delta and C fibres) + release of Substance P and CGRP from sensory neurons → peripheral sensitization
- Inflammatory mediator release: Stimulates production of IL-6, IL-8, TNF-α from endothelial and immune cells
- Smooth muscle contraction: Bronchial, GI tract → bronchoconstriction, cramping
Degradation:
- ACE (angiotensin-converting enzyme) cleaves bradykinin → inactive fragments (primary pathway)
- Aminopeptidase P, carboxypeptidase N (secondary pathways)
- Half-life: 15-30 seconds in circulation
graph TD
A[Tissue Injury / Contact Activation] --> B[Kallikrein Activation]
B --> C[HMWK Cleavage]
C --> D[Bradykinin Release]
D --> E[B2 Receptor - Constitutive]
D --> F[B1 Receptor - Inducible]
E --> G["Gq → PLC → IP3/DAG"]
F --> G
G --> H["Ca²⁺ Release"]
H --> I["eNOS → NO → Vasodilation"]
H --> J["PLA2 → AA → COX-2 → PGE2"]
H --> K["MLCK → Endothelial Contraction → Permeability"]
H --> L["Nociceptor Activation → Pain"]
J --> M["Pain Sensitization + Inflammation"]
D --> N[ACE Degradation]
N --> O[Inactive Fragments]
P[ACE Inhibitors] -.Block.-> N
P --> Q["Bradykinin Accumulation → Cough/Angioedema"]
¶ Pain and Inflammation
Bradykinin is a central mediator of inflammatory pain—it lowers the activation threshold of TRPV1 channels on nociceptors, making tissue more sensitive to heat, acid (tissue acidosis), and mechanical stimuli. In conditions like fibromyalgia, rheumatoid arthritis, and wound healing, elevated local bradykinin perpetuates hyperalgesia. B1 receptor upregulation in chronic inflammation creates a positive feedback loop (more inflammation → more B1 → more bradykinin sensitivity → more pain), explaining why some inflammatory pain becomes self-sustaining.
¶ Vascular Permeability and Edema
Bradykinin is among the most potent endogenous permeability factors (10-100x more potent than histamine). It causes endothelial cells to round up and contract, creating intercellular gaps that allow plasma protein leakage → oncotic pressure shift → edema. This is critical in wound healing (needed for immune cell recruitment) but pathological in conditions like hereditary angioedema (C1 esterase inhibitor deficiency → uncontrolled bradykinin production → life-threatening swelling).
ACE inhibitors (used for hypertension, heart failure) reduce angiotensin II formation but also prevent bradykinin degradation. This leads to:
- Chronic dry cough (10-15% of patients): bradykinin accumulation in bronchial tissue → airway irritation, Substance P release
- Angioedema (0.1-0.7% of patients): bradykinin-induced permeability in face, lips, tongue, larynx → medical emergency
- Therapeutic advantage: increased NO production → enhanced vasodilation, cardioprotection
¶ Evolutionary and Metamodel Context
From an evolutionary medicine perspective, the kallikrein-kinin system represents an ancient alarm mechanism conserved across vertebrates—it ensures rapid local inflammation when tissue integrity is breached. However, the mismatch arises when this system is chronically activated by:
- Metabolic inflammation (obesity, insulin resistance): adipose tissue kallikrein activity → bradykinin → vascular leak → edema in legs (common in metabolic syndrome)
- Chronic pain syndromes: central sensitization amplifies bradykinin signaling (Metamodel 3: loss of context regulation)
- ACE inhibitor use: pharmacological disruption of degradation pathway → modern drug-induced phenotype unknown to natural selection
- B2 antagonists (icatibant): used for hereditary angioedema (emergency rescue)
- ACE inhibitor management: if cough/angioedema develops → switch to ARB (angiotensin receptor blocker, does not affect bradykinin)
- Natural bradykinin modulation: Quercetin, bromelain may reduce kallikrein activity (theoretical anti-inflammatory mechanism)
- Lifestyle: chronic low-grade inflammation reduction (diet, exercise, stress management) indirectly reduces bradykinin generation
- 9-amino-acid peptide cleaved from high-molecular-weight kininogen (HMWK) by kallikrein enzymes
- Half-life 15-30 seconds in plasma due to rapid ACE degradation
- B2 receptor: constitutive GPCR on endothelial cells, neurons, smooth muscle
- B1 receptor: inducible GPCR, upregulated by IL-1β, TNF-α during chronic inflammation
- 10-100x more potent than histamine for vascular permeability induction
- ACE inhibitor use → 10-15% develop chronic cough, 0.1-0.7% angioedema (bradykinin accumulation)
- Nociceptor sensitization: directly activates TRPV1 and reduces activation threshold for heat/acid
- Downstream mediators: stimulates PGE2, Nitric Oxide, Substance P, CGRP release
- Hereditary angioedema: C1 esterase inhibitor deficiency → uncontrolled kallikrein → excessive bradykinin → life-threatening swelling
- Clinical measurement: not routinely measured (too short half-life); infer activity from symptoms + context (ACE inhibitor use, angioedema)
- Inflammation — bradykinin is a primary early inflammatory mediator driving vascular response
- Pain — sensitizes peripheral nociceptors, lowers TRPV1 threshold, critical for inflammatory pain
- Vascular permeability — one of the most potent endogenous permeability factors, causes endothelial gaps
- ACE — primary degradation enzyme; ACE inhibitors block bradykinin breakdown
- Kallikrein — serine protease that cleaves kininogen to generate bradykinin
- Nitric Oxide — bradykinin stimulates eNOS → NO production → vasodilation
- PGE2 — bradykinin activates PLA2 → arachidonic acid → COX-2 → PGE2 synthesis
- TRPV1 — bradykinin lowers activation threshold, enhances heat and acid sensitivity
- Substance P — released from sensory neurons in response to bradykinin, amplifies pain
- CGRP — co-released with Substance P during bradykinin-induced nociceptor activation
- IL-1β — upregulates B1 receptor expression during chronic inflammation
- TNF-α — synergizes with IL-1β to induce B1 receptor, perpetuates bradykinin sensitivity
- Histamine — co-mediator of vascular permeability from mast cells, but less potent than bradykinin
- angiotensin II — ACE generates Ang II while degrading bradykinin (dual substrate)
- Wound Healing - The Complete Cellular Picture — bradykinin essential for early permeability phase, immune cell recruitment
- Edema — bradykinin-induced vascular leak is primary mechanism in inflammatory edema
- Mast cells — release bradykinin precursors and amplify bradykinin effects via histamine
- COX-2 — induced by bradykinin signaling, produces prostaglandins that sustain inflammation
- fibromyalgia — chronic bradykinin signaling may contribute to widespread pain and central sensitization
- rheumatoid arthritis — elevated synovial bradykinin contributes to joint pain and swelling
- tissue acidosis — acidic pH potentiates bradykinin effects on TRPV1, worsening pain
- endothelial cells — primary target of bradykinin; contraction creates intercellular gaps for permeability
- module-05-summary.md: Mast cells release bradykinin alongside histamine and prostaglandins during degranulation
- pain-walkthrough.md: Bradykinin lowers TRPV1 activation threshold, making nociceptors hypersensitive to protons and heat
- wound-healing-walkthrough.md: Bradykinin is a potent mediator of vascular permeability, creating endothelial gaps essential for immune cell infiltration during inflammatory phase